Robert S. Matson is president and co-founder of QuantiScientifics, LLC. The company is involved in the commercialization of multiplexed assays for life science, clinical research, and in vitro diagnostics. Previously, Matson was involved in the research and development of microarray technologies, detection chemistries, as well as point-of-care devices for more than 17 years while at Beckman Coulter, Inc. He participated in the National Institute of Standards and Technology’s (NIST) Advanced Technology Program sponsored Genosensor Consortium and collaborated with Sir Edwin Southern on the development of an in situ oligonucleotide array synthesis platform for the corporation. Other work included development of the A2 MicroArray System, a microplate-based array platform for multiplexed micro-ELISA, which QuantiScientifics recently licensed for commercialization.
"""This publication offers a detailed perspective and insight into the present and future uses of this technology"" Anticancer Research ""A basic reference on the benefits of microarray technology in drug discovery, this publication offers a detailed perspective and insight into the present and future uses of this technology."" Anticancer Research"